Health Affairs, 28, no. 3 (2009): 724-733
doi: 10.1377/hlthaff.28.3.724
© 2009 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (1)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Busch, S. H.
* Articles by Barry, C. L.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Busch, S. H.
* Articles by Barry, C. L.
Related Collections
* Legal/Regulatory Issues
* Maternal And Child Health
* Mental Health/Substance Abuse
* Pharmaceuticals
* Consumer Issues
*Related Articles

Pharmaceuticals

Pediatric Antidepressant Use After The Black-Box Warning

Susan H. Busch and Colleen L. Barry

In 2004 the Food and Drug Administration (FDA) required a black-box warning on antidepressants that describes a possible suicide risk in children. An analysis of the events, evidence, and FDA actions reveals information asymmetries that affect various players’ ability to identify and act on risks. Antidepressant use declined sharply overall, not just among children, and the FDA’s emphasis on the proven efficacy of fluoxetine (generic Prozac) did not prompt dramatic shifts in prescribing. We conclude that risk communication strategies need to be refined, to ensure intended results.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?

Related Articles


  • Pharmaceuticals & Psychotropic Drugs
    Health Affairs, May/June 2009; 28(3): 723
    [Extract] [Full Text] [PDF]
     
  • Haiden A. Huskamp, Alisa B. Busch, Marisa E. Domino, and Sharon-Lise T. Normand
    Antidepressant Reformulations: Who Uses Them, And What Are The Benefits?
    Health Affairs, May/June 2009; 28(3): 734-745.
    [Abstract] [Full Text] [PDF] [Appendix]
     
  • Julie M. Donohue, Haiden A. Huskamp, and Samuel H. Zuvekas
    Dual Eligibles With Mental Disorders And Medicare Part D: How Are They Faring?
    Health Affairs, May/June 2009; 28(3): 746-759.
    [Abstract] [Full Text] [Figures Only] [PDF]
     


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
E. R. Dorsey, A. Rabbani, S. A. Gallagher, R. M. Conti, and G. C. Alexander
Impact of FDA Black Box Advisory on Antipsychotic Medication Use
Arch Intern Med, January 11, 2010; 170(1): 96 - 103.
[Abstract] [Full Text] [PDF]